Article information
Full text is only aviable in PDF
Bibliografía
[1.]
J. Rosack.
SSRIs Called on carpet over violence claims.
Psychiatr News, 36 (2001), pp. 6
[2.]
P.J. Cowen.
Panorama: «the secrets of Seroxat».
BMJ, 325 (2002), pp. 910
[3.]
C. Medawar, A. Herxheimer, A. Bell, S. Jofre.
Paroxetine, panorama and user reporting of ADRs: consumer intelligence matters in clinical practice and post-marketing drug surveillance.
Int J Risk Safety Med, 15 (2002), pp. 161-169
[4.]
G. Watts.
Is this journalism that makes a difference?.
BMJ, 326 (2003), pp. 1093
[5.]
D. Bachtold.
Conflict-of-interest allegations derail inquiry into antidepressant’s «dark side».
Science, 300 (2003), pp. 33
[6.]
J. Lenzer.
Secret US report surfaces on antidepressants in children.
BMJ, 329 (2004), pp. 307
[7.]
H. Melander, J. Ahlqvist-Rastad, G. Meijer, B. Beermann.
Evidence b(i)ased medicine: selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications.
BMJ, 326 (2003), pp. 1171-1175
[8.]
J.N. Jureidini, C.J. Doecke, P.R. Mansfield, M.M. Haby, D.B. Menkes, A.L. Tonkin.
Efficacy and safety of antidepressants for children and adolescents.
BMJ, 328 (2004), pp. 879-883
[9.]
W. Kondro, B. Sibbad.
Drug company experts advised staff to withhold data about SSRI use in children.
Can Med Assoc J, 170 (2004), pp. 283
[10.]
C.J. Whittington, T. Kendall, P. Fonagy, D. Cottrell, A. Cotgrove, E. Boddington.
Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data.
Lancet, 363 (2004), pp. 1341-1345
[11.]
O. Dyer.
GlaxoSmithKline faces US lawsuit over concealment of trial results.
BMJ, 328 (2004), pp. 1395
[12]
Los psiquiatras creemos que los ISRS son eficaces en niños. El Correo Farmacéutico, 12 de abril de 2004.
[13]
Reino Unido recomienda que no se venda un antidepresivo a menores. El mundo, 10 de junio de 2003.
[14.]
F. Waechter.
Paroxetine must not be given to patients under 18.
BMJ, 326 (2003), pp. 1282
[15.]
A. Khan, S. Khan, R. Kolts, W.A. Brown.
Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports.
Am J Psychiatry, 160 (2003), pp. 790-792
[16.]
G.M. McClure.
Suicide in children and adolescents in England and Wales 1970-1998.
Br J Psychiatry, 178 (2001), pp. 469-474
[17.]
M. Olfson, D. Shaffer, S.C. Marcus, T. Greenberg.
Relationship between antidepressant medication treatment and suicide in adolescents.
Arch Gen Psychiatry, 60 (2003), pp. 978-982
[18.]
W.D. Hall, A. Mant, P.B. Mitchell, V.A. Rendle, I.B. Hickie, P. McManus.
Association between antidepressant prescribing and suicide in Australia, 1991-2000: trend analysis.
BMJ, 326 (2003), pp. 1008
[19.]
T. Helgason, H. Tomasson, T. Zoega.
Antidepressants and public health in Iceland. Time series analysis of national data.
Br J Psychiatry, 184 (2004), pp. 157-162
[20.]
H. Jick, J.A. Kaye, S.S. Jick.
Antidepressants and the risk of suicidal behaviors.
JAMA, 292 (2004), pp. 338-343
Copyright © 2005. Sociedad Española de Salud Pública y Administración Sanitaria
